收藏切换
Pharmacological effect and mechanism of Ligustri Lucidi Fructus in chronic obstructive pulmonary disease
收藏切换
Chinese Traditional and Herbal Drugs | 2025, 56(10) : 3771 - 3778
Less
收藏切换
Chinese Traditional and Herbal Drugs | 2025, 56(10): 3771-3778
Pharmacological effect and mechanism of Ligustri Lucidi Fructus in chronic obstructive pulmonary disease
Full
ZHAO Aijun1, MA Qinguo2, WANG Tingting2, LUO Yanyan2, RUAN Zhicheng1, WU Xiaojuan1, WANG Hongli1,2,3
Affiliations
    1 Gansu University of Chinese Medicine, Lanzhou 730000, China;
    2 Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China;
    3 Northwest Normal University, Lanzhou 730070, China
doi: 10.7501/j.issn.0253-2670.2025.10.033
Outline
收藏切换
Chronic obstructive pulmonary disease (COPD) is a global public health problem with chronic airway inflammation, oxidative stress, and immune imbalance as its core pathological mechanisms. Current treatment methods mainly focus on relieving symptoms and reducing acute exacerbations, but it is difficult to prevent the continued progression of the disease. In recent years, the potential of traditional Chinese medicine in the prevention and treatment of COPD has gradually received attention, among which Nüzhenzi (Ligustri Lucidi Fructus, LLF) has been highly valued for its rich active ingredients and multi-target pharmacological effects. Research has shown that glycosides (such as salidroside and Ligustrum lucidum glycoside) and triterpenoids (such as oleanolic acid and ursolic acid) in LLF have significant anti-inflammatory, antioxidant, and immunomodulatory effects, which can effectively intervene in the core pathological process of COPD by regulating signaling pathways such as nuclear factor NF-κB, nuclear factor erythroid 2-related factor 2 (Nrf2), and Th17/Treg balance. In addition, the research results of LLF in respiratory diseases such as asthma and pulmonary fibrosis also provide theoretical basis for its application in COPD. However, current research on the specific mechanism of action and clinical efficacy of LLF in COPD is still limited, and further validation of its therapeutic effect is needed through animal models, cell experiments, and randomized controlled clinical trials. This article reviews the main active ingredients and pharmacological effects of LLF, and explores its potential application value in the treatment of COPD based on its pathological characteristics, providing theoretical support for subsequent research.
chronic obstructive pulmonary disease  /  Ligustri Lucidi Fructus  /  anti-inflammatory  /  antioxidant  /  immunomodulatory  /  rhodiola glycoside  /  Ligustrum lucidum glycoside  /  oleanolic acid  /  ursolic acid
赵爱军, 马琴国, 王婷婷, 罗燕燕, 阮治铖, 武小娟, 王红丽. 女贞子在慢性阻塞性肺疾病中的药理作用与机制. 中草药, 2025 , 56 (10) : 3771 -3778 . DOI: 10.7501/j.issn.0253-2670.2025.10.033
ZHAO Aijun, MA Qinguo, WANG Tingting, LUO Yanyan, RUAN Zhicheng, WU Xiaojuan, WANG Hongli. Pharmacological effect and mechanism of Ligustri Lucidi Fructus in chronic obstructive pulmonary disease[J]. Chinese Traditional and Herbal Drugs, 2025 , 56 (10) : 3771 -3778 . DOI: 10.7501/j.issn.0253-2670.2025.10.033
Year 2025 volume 56 Issue 10
45
8
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.10.033
  • Receive Date:2024-12-02
  • Online Date:2026-11-13
Article Data
Affiliations
History
  • Received:2024-12-02
Affiliations
References
Share
https://castjournals.cast.org.cn/joweb/zcy/EN/10.7501/j.issn.0253-2670.2025.10.033
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT